PolmanCHReingoldSCBanwellB. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol2011; 69: 292–302.
2.
LublinFDReingoldSCCohenJA. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology2014; 83: 278–286.
3.
KurtzkeJF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology1983; 33: 1444–1452.
4.
VrenkenHJenkinsonMHorsfieldMA. Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol2013; 260: 2458–2471.
5.
DurelliLVerdunEBarberoP. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2 year prospective randomized multicentre study (INCOMIN). Lancet2002; 359: 1453–1460.
6.
Koch-HenriksenNSorensenPSChristensenT. A randomised study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology2006; 66: 1056–1060.
7.
PanitchHGoodinDSFrancisG. Randomized, comparative study of interferon β-1a treatment regimens in MS. The EVIDENCE Trial. Neurology2002; 59: 1496–1506.
8.
CohenJAColesAJArnoldDL. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet2012; 380: 1819–1828.
9.
ColesAJTwymanCLArnoldDL. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet2012; 380: 1829–1839.
10.
CastellaniJ. Head to head; are clinical trial data shared sufficiently today? Yes. BMJ2013; 347: f1881.
11.
FilippiniGDel GiovaneCVacchiL. Immunomodulators and immunosuppressants for multiple sclerosis: Network meta-analysis. Cochrane Database Syst Rev2013; 6: CD008933.
12.
Del SantoFMarateaDFaddaV. Treatments for relapsing-remitting multiple sclerosis: Summarising current information by network meta-analysis. Eur J Clin Pharmacol2012; 68: 441–448.
13.
HurwitzBJ. Registry studies of long-term multiple sclerosis outcomes: Description of key registries. Neurology2011; 76(Suppl 1): S3–S6.
14.
PalaceJBregenzerTTremlettH. UK multiple sclerosis risk-sharing scheme: A new natural history dataset and an improved Markov model. BMJ Open2014; 4: e004073.
